Carboplatin and programmed death-ligand 1 blockade synergistically produce a similar antitumor effect to carboplatin alone in murine ID8 ovarian cancer model-Reference-Cited by-同舟云学术

Carboplatin and programmed death-ligand 1 blockade synergistically produce a similar antitumor effect to carboplatin alone in murine ID8 ovarian cancer model

Published:2017-11-24 Issue:2 Volume:44 Page:303-311
ISSN:1341-8076
Container-title:Journal of Obstetrics and Gynaecology Research
language:en
Short-container-title:J. Obstet. Gynaecol. Res.

Author:

Zhu Xinxin¹,Xu Jia²,Cai Han¹,Lang Jinghe¹^ORCID

Affiliation:

1. Department of Obstetrics and Gynecology; Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences; Beijing China

2. Department of Immunology and Center for Immunotherapy; Institute of Basic Medical Sciences, Peking Union Medical College, Chinese Academy of Medical Sciences; Beijing China

Publisher

Wiley

Subject

Obstetrics and Gynecology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/jog.13521/fullpdf

Reference34 articles.

1. Global cancer statistics, 2012;Torre;CA Cancer J Clin,2015

2. Cancer statistics, 2012;Siegel;CA Cancer J Clin,2012

3. Current approaches and challenges in managing and monitoring treatment response in ovarian cancer;Marcus;J Cancer,2014

4. Primary ovarian cancer chemotherapy: Current standards of care;WP;Br J Cancer,2003

5. Multiple differential networks strategy reveals carboplatin and melphalan-induced dynamic module changes in retinoblastoma;Chen;Med Sci Monit,2016

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Development of Platinum Complexes for Tumor Chemoimmunotherapy;Chemistry – A European Journal;2024-01-03

2. EXPRESSION OF PROGRAMMED CELL DEATH PROTEIN 1 (PD-1) AND ITS LIGAND PD-L1 IN HIGH-GRADE SEROUS OVARIAN CANCER;Ulyanovsk Medico-biological Journal;2023-09-29

3. Doxorubicin—An Agent with Multiple Mechanisms of Anticancer Activity;Cells;2023-02-19

4. PD-1/PD-L1 and DNA Damage Response in Cancer;Cells;2023-02-07

5. A Phase 2 Clinical Trial of Combination Nivolumab, Ipilimumab, and Paclitaxel in Patients With Untreated Metastatic NSCLC: The OPTIMAL Trial;JTO Clinical and Research Reports;2022-06